A cup of coffee with artificial sweetener and a prescription antidepressant may interact in ways no one anticipated — not in your liver, but in your gut microbiome. A systematic study published in Molecular Systems Biology tested 39 commercially used sweeteners against 25 species of human gut bacteria and found that roughly 75% of them directly affected bacterial growth. More strikingly, when combined with common medications and food additives, some sweeteners produced synergistic effects that suppressed beneficial bacteria far more than either compound alone.
The study, led by Professor Kiran Raosaheb Patil and Dr Sonja Blasche at the MRC Toxicology Unit, University of Cambridge, is the most comprehensive in vitro survey of sweetener-bacteria interactions to date. It tested every major category of sweetener — artificial (aspartame, sucralose, saccharin, neotame, acesulfame-K), sugar alcohols (erythritol, xylitol, sorbitol, maltitol), natural (stevia derivatives, monk fruit, thaumatin), and rare sugars (allulose, tagatose) — against a panel of 25 bacterial species that represent the major phyla of the human gut microbiome.
What they found
Of the 975 sweetener-bacteria pairs tested, the researchers identified 30 verified direct interactions involving 26 sweeteners and 5 bacterial strains. The most sensitive bacteria were Clostridium symbiosum and Lacrimispora saccharolytica, both affected by the largest number of compounds. The most potent individual sweetener was isosteviol, a derivative of stevia, which inhibited three bacterial species and promoted one.
But the study’s most provocative finding emerged when the researchers combined sweeteners with co-consumed compounds: caffeine, vanillin, the artificial sweetener advantame, and the widely prescribed antidepressant duloxetine (Cymbalta, taken by over 4.2 million people in the US). They also tested sweetener combinations with 8 common tablet-formulated drugs including ibuprofen, acetaminophen, and risperidone.
In total, 102 compound-compound interactions were identified — 68 antagonistic (weaker-than-expected effects) and 34 synergistic (stronger-than-expected effects). The strongest synergy occurred between isosteviol and duloxetine against Roseburia intestinalis, a butyrate-producing bacterium linked to digestive health and blood sugar regulation. In the combination, butyric acid concentrations dropped by more than 25 percent, while glutamine levels rose by roughly 50 percent.
The mechanism
Using a multi-omics approach combining proteomics, metabolomics, and transposon library screening, the team traced the synergy to a surprising root cause. Roseburia intestinalis accumulated isosteviol only when duloxetine was also present — not when isosteviol was administered alone. Duloxetine appeared to alter the bacterial membrane’s transport systems, effectively opening the door for isosteviol to enter the cell and cause toxicity.
“In vitro, we found that duloxetine disrupts the membrane transport of these bacteria, allowing isosteviol to enter and cause damage,” said Patil. “This is not a simple additive effect — the synergy arises from a genuine biological interaction at the membrane level.”
In a synthetic 25-species microbial community, the isosteviol-duloxetine combination significantly reduced Shannon diversity, a standard measure of ecosystem health. Two species were particularly suppressed: Roseburia intestinalis and Parabacteroides merdae, both associated with positive health outcomes. The community supernatant also increased toxicity in HeLa cells and altered cytokine secretion in Caco-2 intestinal cells, with IL-6 and IL-8 dropping by more than 75 percent.
Important caveats
The study is an in vitro model — laboratory cultures of bacteria grown in a single medium at a single concentration (50 microM, estimated as colon-relevant). Real human guts contain hundreds of species, and sweeteners are absorbed, metabolized, diluted, and chemically altered before reaching the colon. The researchers emphasize that these findings cannot be directly extrapolated to health outcomes in humans.
“Sugar alternatives are often marketed as metabolically neutral, but our study challenges this idea,” said Blasche. “We found that they can directly affect gut bacteria, particularly when mixed with other compounds such as medication and food additives.”
Sources
- Blasche S, Periwal V, et al. “Common xenobiotics modulate gut microbial responses to low-calorie sweeteners in vitro.” Molecular Systems Biology 22(6), 2026. DOI: 10.1038/s44320-026-00225-6
- University of Cambridge press release via ScienceDaily